See more : j-Group Holdings Corp. (3063.T) Income Statement Analysis – Financial Results
Complete financial analysis of MusclePharm Corporation (MSLP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MusclePharm Corporation, a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Greggs plc (GGGSF) Income Statement Analysis – Financial Results
- Galaxia SM, Inc. (011420.KS) Income Statement Analysis – Financial Results
- Alankit Limited (ALANKIT.NS) Income Statement Analysis – Financial Results
- New Century Healthcare Holding Co. Limited (1518.HK) Income Statement Analysis – Financial Results
- Community Investors Bancorp, Inc. (CIBN) Income Statement Analysis – Financial Results
MusclePharm Corporation (MSLP)
About MusclePharm Corporation
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada. On December 15, 2022, MusclePharm Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Nevada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.04M | 64.44M | 79.67M | 88.11M | 102.16M | 132.50M | 166.86M | 177.39M | 110.88M | 67.06M | 20.84M | 4.05M | 1.02M | 0.00 | 7.98K |
| Cost of Revenue | 44.67M | 44.83M | 70.98M | 69.72M | 71.71M | 88.03M | 109.93M | 121.38M | 77.69M | 52.73M | 14.47M | 2.80M | 922.97K | 0.00 | 0.00 |
| Gross Profit | 5.37M | 19.61M | 8.69M | 18.39M | 30.45M | 44.47M | 56.93M | 56.01M | 33.19M | 14.33M | 6.37M | 1.24M | 94.95K | 0.00 | 7.98K |
| Gross Profit Ratio | 10.73% | 30.43% | 10.91% | 20.88% | 29.80% | 33.56% | 34.12% | 31.57% | 29.94% | 21.37% | 30.56% | 30.71% | 9.33% | 0.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 893.00K | 751.00K | 642.00K | 1.87M | 4.25M | 4.00M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 16.33M | 20.42M | 22.54M | 25.58M | 39.71M | 57.35M | 43.34M | 30.84M | 14.63M | 22.59M | 19.49M | 822.32K | 20.26K | 1.00M |
| Selling & Marketing | 4.39M | 507.00K | 2.49M | 2.94M | 9.35M | 10.65M | 26.99M | 28.05M | 15.53M | 8.43M | 0.00 | 0.00 | 1.07M | 4.17K | 1.62K |
| SG&A | 4.39M | 16.84M | 22.90M | 25.48M | 34.94M | 50.36M | 84.33M | 71.39M | 46.37M | 23.06M | 22.59M | 19.49M | 1.89M | 24.43K | 1.00M |
| Other Expenses | 9.89M | 9.87M | 14.00M | 0.00 | 1.88M | 35.32M | 83.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.40K | -48.85K | 0.00 |
| Operating Expenses | 14.28M | 16.84M | 23.80M | 26.23M | 37.45M | 52.23M | 88.59M | 75.39M | 47.49M | 23.06M | 22.59M | 19.49M | 1.91M | -24.43K | 1.00M |
| Cost & Expenses | 58.96M | 61.67M | 94.77M | 95.95M | 109.16M | 140.26M | 198.51M | 196.77M | 125.17M | 75.79M | 37.06M | 22.30M | 2.83M | 24.43K | 1.00M |
| Interest Income | 0.00 | 675.00K | 383.00K | 18.00K | -837.00K | 0.00 | 0.00 | 223.00K | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.46M | 1.70M | 3.76M | 3.80M | 3.26M | 1.64M | 779.00K | 201.00K | 783.32K | 7.34M | 3.71M | 480.59K | 102.39K | 0.00 | 0.00 |
| Depreciation & Amortization | 331.00K | 465.00K | 659.00K | 849.00K | 1.46M | 2.13M | 2.82M | 1.98M | 708.98K | 475.32K | 171.59K | 787.20K | 7.95K | 0.00 | 0.00 |
| EBITDA | -8.91M | 5.33M | -14.43M | -6.01M | -7.19M | 610.00K | -48.16M | -11.62M | -14.30M | -8.74M | -19.40M | -18.30M | -1.80M | -24.43K | -995.89K |
| EBITDA Ratio | -14.12% | 8.27% | -18.11% | -6.82% | -5.98% | 0.46% | -28.86% | -6.55% | -14.53% | -16.62% | -93.09% | -452.19% | -177.14% | 0.00% | -12,481.39% |
| Operating Income | -7.40M | 4.86M | -15.09M | -6.86M | -7.57M | -1.52M | -50.97M | -13.60M | -16.82M | -11.62M | -19.57M | -19.09M | -1.81M | -24.43K | -995.89K |
| Operating Income Ratio | -14.78% | 7.54% | -18.94% | -7.78% | -7.41% | -1.14% | -30.55% | -7.67% | -15.17% | -17.33% | -93.91% | -471.64% | -177.92% | 0.00% | -12,481.39% |
| Total Other Income/Expenses | -5.48M | 564.00K | -3.76M | -3.80M | -3.64M | 5.50M | -779.00K | -201.00K | -783.32K | -7.34M | -3.35M | -836.91K | -6.45K | 0.00 | 0.00 |
| Income Before Tax | -12.87M | 3.17M | -18.84M | -10.66M | -10.83M | -3.16M | -51.75M | -13.80M | -17.60M | -18.95M | -22.92M | -19.93M | -1.82M | -24.43K | -995.89K |
| Income Before Tax Ratio | -25.73% | 4.91% | -23.65% | -12.09% | -10.60% | -2.38% | -31.02% | -7.78% | -15.88% | -28.26% | -109.99% | -492.32% | -178.55% | 0.00% | -12,481.39% |
| Income Tax Expense | 8.00K | -19.00K | 86.00K | 100.00K | 142.00K | 318.00K | 105.00K | 33.00K | 115.48K | 7.34M | 3.71M | 480.59K | 102.39K | 0.00 | 0.00 |
| Net Income | -12.88M | 3.19M | -18.93M | -10.76M | -10.97M | -3.48M | -51.86M | -13.83M | -17.72M | -26.29M | -26.63M | -20.41M | -1.92M | -24.43K | -995.89K |
| Net Income Ratio | -25.74% | 4.94% | -23.76% | -12.21% | -10.74% | -2.62% | -31.08% | -7.80% | -15.98% | -39.20% | -127.80% | -504.19% | -188.61% | 0.00% | -12,481.39% |
| EPS | -0.31 | 0.08 | -0.92 | -0.72 | -0.79 | -0.26 | -3.81 | -1.25 | -2.46 | -18.02 | -80.45 | -421.77 | -3.74K | -47.52 | -1.94K |
| EPS Diluted | -0.31 | 0.08 | -0.92 | -0.72 | -0.79 | -0.26 | -3.81 | -1.25 | -2.46 | -18.02 | -80.45 | -421.77 | -3.74K | -47.52 | -1.94K |
| Weighted Avg Shares Out | 41.17M | 41.17M | 20.48M | 15.02M | 13.88M | 13.44M | 13.62M | 11.07M | 7.19M | 1.46M | 331.03K | 48.38K | 514.00 | 514.00 | 514.00 |
| Weighted Avg Shares Out (Dil) | 41.17M | 41.17M | 20.48M | 15.02M | 13.88M | 13.44M | 13.62M | 11.07M | 7.19M | 1.46M | 331.03K | 48.38K | 514.00 | 514.00 | 514.00 |
MusclePharm Files For Uplisting IPO To Nasdaq
MusclePharm has filed to raise capital via an uplisting IPO to Nasdaq. The firm sells a variety of sports nutrition and functional energy products.
MusclePharm to Present at the LD Micro Invitational XII Conference
LAS VEGAS, May 24, 2022 (GLOBE NEWSWIRE) -- MusclePharm Corporation (“MusclePharm” or the “Company”) (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today announced that Ryan Drexler, the Company's Chief Executive Officer, and Sabina...
MusclePharm Corporation (MSLP) CEO Ryan Drexler on Q1 2022 Results - Earnings Call Transcript
MusclePharm Corporation (OTCPK:MSLP) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Ryan Drexler - Chairman & Chief Executive Officer Sabina Rizvi - President & Chief Financial Officer John Mills - Managing Partner-ICR, Inc. Conference Call...
MusclePharm to Announce Fourth Quarter and Full Year 2021 Financial Results on Thursday, April 14, 2022
LAS VEGAS, April 12, 2022 (GLOBE NEWSWIRE) -- MusclePharm Corporation (“MusclePharm” or the “Company”) (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, announced today that the Company will report its financial results for the...
MusclePharm Corporation (MSLP) CEO Ryan Drexler on Q3 2021 Results - Earnings Call Transcript
MusclePharm Corporation (MSLP) CEO Ryan Drexler on Q3 2021 Results - Earnings Call Transcript
MusclePharm to Announce Third Quarter 2021 Financial Results on Monday, November 15, 2021
CALABASAS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, announced today that the Company will report its financial results for the third quarter ended September...
MusclePharm Announces Closing of $7.0 Million Senior Secured Notes Offering
CALABASAS, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds...
MusclePharm Closes More Pre-Orders Reaching Pre-Production Sales Goal of $1 Million for MP Performance Energy Line Through Collective Distributors
CALABASAS, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- MusclePharm Corporation (OTCMKTS: MSLP), a global provider of leading sports nutrition & lifestyle branded nutritional supplements, today reported that they have closed $1.0 million to date in pre-orders for MP Performance Energy,...
MusclePharm's (MSLP) CEO Ryan Drexler on Q2 2021 Results - Earnings Call Transcript
MusclePharm's (MSLP) CEO Ryan Drexler on Q2 2021 Results - Earnings Call Transcript
MusclePharm Increases Sequential Sales in Second Quarter 2021 Despite Continued Industry Wide Supply Chain Challenges
Company Delivers 14% Sequential Net Revenue Growth in Second Quarter 2021
Source: https://incomestatements.info
Category: Stock Reports